

# Shaun G Goodman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1470050/publications.pdf>

Version: 2024-02-01

446  
papers

36,918  
citations

4370

86  
h-index

3476

182  
g-index

469  
all docs

469  
docs citations

469  
times ranked

23280  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. <i>CJC Open</i> , 2022, 4, 180-188.	0.7	2
2	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018. <i>CJC Open</i> , 2022, 4, 206-213.	0.7	5
3	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). <i>Heart and Vessels</i> , 2022, 37, 1291-1298.	0.5	3
4	Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
5	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
6	ABCDâ€¢GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILORâ€¢PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024156.	1.6	22
7	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. <i>Advances in Therapy</i> , 2022, 39, 1832-1843.	1.3	1
8	Objective risk assessment vs standard care for acute coronary syndromesâ€¢The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation. <i>BMC Health Services Research</i> , 2022, 22, 380.	0.9	1
9	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307.	1.6	11
10	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
11	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	5.5	19
12	Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. <i>Current Oncology</i> , 2022, 29, 2504-2508.	0.9	1
13	Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2022, 248, 35-41.	1.2	0
14	Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. <i>JMIR Formative Research</i> , 2022, 6, e34080.	0.7	2
15	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	1.0	23
16	Point of care CYP2C19 genotyping after percutaneous coronary intervention. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	0
17	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	1.2	4
18	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	1
20	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	1.3	6
21	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. <i>American Heart Journal</i> , 2021, 232, 84-93.	1.2	10
22	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021, 231, 18-24.	1.2	12
23	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	0.8	33
24	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
25	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021, 75, e13861.	0.8	3
26	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 140, 62-68.	0.7	20
27	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	3.8	65
28	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
29	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. <i>Canadian Journal of Diabetes</i> , 2021, .	0.4	1
30	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2021, 6, 304.	3.0	29
31	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
32	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 222-228.	1.8	2
33	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
34	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
35	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27% of 979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006646.	0.9	13
36	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 739-750.	1.1	90

#	ARTICLE	IF	CITATIONS
37	Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. <i>Clinical Cardiology</i> , 2021, 44, 839-847.	0.7	3
38	Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 152, 49-56.	0.7	5
39	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. <i>CJC Open</i> , 2021, 3, 758-768.	0.7	1
40	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. <i>CJC Open</i> , 2021, 3, 1419-1427.	0.7	1
41	Early invasive coronary angiography and acute ischaemic heart failure outcomes. <i>European Heart Journal</i> , 2021, 42, 3756-3766.	1.0	10
42	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14597.	0.8	2
43	Treatment Inertia in Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e020126.	1.6	7
44	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study. <i>CJC Open</i> , 2021, 3, 1463-1470.	0.7	1
45	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
46	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
47	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
48	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107997.	1.2	2
49	Factors associated with actively working in the very long-term following acute coronary syndrome. <i>Clinics</i> , 2021, 76, e2553.	0.6	0
50	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e020708.	1.6	1
51	Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469,749 Adults From 2 Canadian Provinces. <i>Journal of the American Heart Association</i> , 2021, 10, e022330.	1.6	11
52	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <i>Journal of Cardiology</i> , 2021, , .	0.8	2
53	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007903.	0.9	5
54	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e023143.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , 2020, 41, 86-94.	1.0	71
56	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Outcomes, 2020, 6, 284-292.	1.8	10
57	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.4	40
58	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	0.7	18
59	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
60	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
61	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	1.0	51
62	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
63	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 065-074.	1.8	11
64	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
65	Cardiac Stress Testing After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2020, 136, 9-14.	0.7	7
66	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7
67	Optimizing screening and management of cardiovascular health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E458-E464.	0.3	9
68	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
69	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020, 74, e13625.	0.8	5
70	Relation of High Lipoprotein(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020, 37, 4568-4584.	1.3	8
71	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	3.8	257
72	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	1.0	35

#	ARTICLE	IF	CITATIONS
73	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	0.7	3
74	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
75	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 418-435.	5.5	105
76	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020, 2, 49-54.	0.7	4
77	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
78	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
79	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
80	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	1.2	50
81	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	0.8	9
82	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2020, 75, 448-451.	1.2	6
83	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
84	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	1.7	30
85	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , 2020, 2, 118-128.	0.7	9
86	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
87	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019, 215, 106-113.	1.2	7
88	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, e54-e55.	0.6	0
89	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
90	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	0.9	17

#	ARTICLE	IF	CITATIONS
91	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
92	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention. <i>JAMA Cardiology</i> , 2019, 4, 1160.	3.0	20
93	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
94	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
95	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
96	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
97	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. <i>Circulation</i> , 2019, 140, 1960-1963.	1.6	7
98	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	1.0	45
99	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	1.2	64
100	USE OF EVIDENCE-BASED PREVENTIVE MEDICAL THERAPIES 1-3 YEARS POST-MYOCARDIAL INFARCTION IN THE PROSPECTIVE GLOBAL TIGRIS REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 169.	1.2	0
101	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
102	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
103	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007811.	1.4	139
104	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
105	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2034.	1.2	0
106	Living alone and cardiovascular disease outcomes. <i>Heart</i> , 2019, 105, 1087-1095.	1.2	26
107	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 160-168.	0.8	4
108	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100

#	ARTICLE	IF	CITATIONS
109	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2019, 35, 653-660.	0.8	56
110	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019, 9, e032165.	0.8	27
111	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 76-83.	0.7	13
112	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
113	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , 2019, 22, 39-45.	0.6	7
114	Sex And Prognostic Significance of Self-Reported Frailty in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	0.8	7
115	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	1.0	23
116	Preâ€“hospital administration of ticagrelor in diabetic patients with STâ€“elevation myocardial infarction undergoing primary angioplasty: A subâ€“analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E369-E377.	0.7	4
117	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
118	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 208-217.	0.4	17
119	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 309-317.	0.4	6
120	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 225-233.	1.0	10
121	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
122	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	1.2	13
123	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. <i>Coronary Artery Disease</i> , 2018, 29, 469-476.	0.3	4
124	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). <i>Clinical Cardiology</i> , 2018, 41, 285-292.	0.7	7
125	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. <i>American Heart Journal</i> , 2018, 200, 96-101.	1.2	117
126	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , 2018, 34, 736-743.	0.8	10



#	ARTICLE	IF	CITATIONS
127	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 309-317.	1.8	12
128	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
129	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	3.0	65
130	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018, 42, 130-137.	0.4	25
131	Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2018, 34, 31-37.	0.8	4
132	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018, 197, 1-8.	1.2	6
133	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , 2018, 196, 56-64.	1.2	10
134	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , 2018, 121, 294-300.	0.7	6
135	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
136	Association of Anemia With Outcomes Among ST-Segment Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007175.	1.4	34
137	Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain MI Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e010394.	1.6	21
138	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
139	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	6.3	1,179
140	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009859.	1.6	60
141	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 3798-3806.	1.0	62
142	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
143	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2018, 122, 944-951.	0.7	11
144	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211

#	ARTICLE	IF	CITATIONS
145	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Canadian Journal of Cardiology, 2018, 34, 1350-1361.	0.8	4
146	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. Canadian Journal of Cardiology, 2017, 33, 166-169.	0.8	13
147	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG. Journal of the American College of Cardiology, 2017, 69, 119-127.	1.2	46
148	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. Journal of the American Heart Association, 2017, 6, .	1.6	52
149	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. International Journal of Cardiology, 2017, 236, 54-60.	0.8	27
150	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. Canadian Journal of Cardiology, 2017, 33, 940-942.	0.8	5
151	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology, 2017, 240, 30-36.	0.8	15
152	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	13.9	593
153	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 1214-1226.	1.5	9
154	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	1.2	26
155	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 214-220.	1.4	2
156	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 582-587.	0.7	8
157	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. Journal of the American College of Cardiology, 2017, 69, 153.	1.2	2
158	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. New England Journal of Medicine, 2017, 376, 2032-2042.	13.9	225
159	Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMI Open, 2017, 7, e015241.	0.8	27
160	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	12
161	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American Heart Journal, 2017, 192, 105-112.	1.2	35
162	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. American Heart Journal, 2017, 193, 46-54.	1.2	2

#	ARTICLE	IF	CITATIONS
163	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 244, 24-29.	0.8	19
164	Stress testing after percutaneous coronary interventions: a population-based study. <i>CMAJ Open</i> , 2017, 5, E417-E423.	1.1	8
165	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	0.8	25
166	Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. <i>International Journal of Cardiology</i> , 2017, 228, 459-464.	0.8	9
167	Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017, 40, 1197-1204.	0.7	12
168	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. <i>EuroIntervention</i> , 2017, 13, 69-77.	1.4	18
169	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 3, ocw051.	1.8	5
170	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 295-301.	0.3	5
171	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016, 218, 291-297.	0.8	8
172	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
173	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016, 102, 1396-1402.	1.2	13
174	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. <i>International Journal of Cardiology</i> , 2016, 222, 86-92.	0.8	3
175	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. <i>American Heart Journal</i> , 2016, 180, 82-89.	1.2	19
176	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). <i>American Heart Journal</i> , 2016, 181, 26-34.	1.2	16
177	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1073.	3.8	80
178	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	1.2	23
179	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
180	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , 2016, 117, 754-759.	0.7	15

#	ARTICLE	IF	CITATIONS
181	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	0.7	13
182	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 214-222.	0.4	11
183	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	1.2	15
184	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. <i>American Heart Journal</i> , 2016, 175, 168-171.	1.2	2
185	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1221.e11-1221.e18.	0.8	7
186	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 646-656.	1.1	31
187	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016, 32, 336-343.	0.8	14
188	Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Journal of Invasive Cardiology</i> , 2016, 28, E203-E210.	0.4	4
189	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 201, 493.	0.8	2
190	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	0.4	68
191	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015, 36, 385-392.	1.0	44
192	Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients) <i>Tj ETQq0 0 OrgBT /Overlock 10 T</i>		
193	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 166-174.	1.1	39
194	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , 2015, 115, 1005-1012.	0.7	3
195	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
196	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
197	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	1.2	13
198	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , 2015, 101, 1554-1561.	1.2	10

#	ARTICLE	IF	CITATIONS
199	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 190, 34-39.	0.8	20
200	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015, 128, 766-775.	0.6	81
201	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 777-787.	1.2	39
202	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	1.2	26
203	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015, 170, 995-1004.e1.	1.2	23
204	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015, 36, 976-983.	1.0	61
205	Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 49.	0.7	14
206	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014, 100, 1456-1461.	1.2	3
207	Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1555-1561.	0.8	5
208	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	1.2	365
209	Targeted Temperature Management Processes and Outcomes After Out-of-Hospital Cardiac Arrest. <i>Critical Care Medicine</i> , 2014, 42, 2565-2574.	0.4	21
210	Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2014, 168, 189-196.e1.	1.2	19
211	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	1.0	145
212	Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 132-137.	0.8	7
213	Prognostic Implications of Prominent R Wave in Electrocardiographic Leads V1 or V2 in Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 113, 1962-1967.	0.7	0
214	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014, 35, 2516-2523.	1.0	83
215	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	1.2	212
216	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26

#	ARTICLE	IF	CITATIONS
217	Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , 2014, 168, 757-765.e3.	1.2	6
218	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	13.9	538
219	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 233-241.	1.0	81
220	Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i> 2014, 114, 955-961.	0.7	9
221	Treatment and Outcomes of Patients With Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian Global Registry of Acute Coronary Events [GRACE]) <i>Tj ETQq1 1,0,784314,rgBT /Ove</i> 202-207.	0.7	23
222	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1586-1592.	0.8	5
223	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 350-358.	0.4	31
224	Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Non-ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1429-1435.	0.8	20
225	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2013, 166, 290-297.	1.2	20
226	Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE]) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i> 112, 51-56.	0.7	4
227	Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1461-1463.	1.2	2
228	Temporal Trends and Referral Factors for Cardiac Rehabilitation Post-Acute Coronary Syndrome in Ontario: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1604-1609.	0.8	10
229	Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes. <i>American Heart Journal</i> , 2013, 166, 58-63.	1.2	49
230	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. <i>American Heart Journal</i> , 2013, 166, 716-722.	1.2	22
231	Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 960-968.	0.8	18
232	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , 2013, 165, 515-522.	1.2	43
233	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. <i>International Journal of Cardiology</i> , 2013, 168, 2720-2725.	0.8	5
234	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. <i>European Heart Journal</i> , 2013, 34, 903-908.	1.0	28

#	ARTICLE	IF	CITATIONS
235	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2013, 24, 321-327.	0.3	3
236	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. <i>Circulation</i> , 2013, 128, 823-833.	1.6	130
237	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
238	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. <i>Heart Asia</i> , 2012, 4, 137-140.	1.1	4
239	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	3.8	200
240	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2012, 164, 343-350.	1.2	7
241	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO". <i>Circulation</i> , 2012, 126, .	1.6	1
242	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	1.8	9
243	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	1.6	176
244	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2012, 163, 66-73.	1.2	168
245	Cardiogenic shock complicating acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2012, 163, 963-971.	1.2	98
246	The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 48-53.	0.8	9
247	Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations From the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 40-47.	0.8	14
248	Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 443-449.	0.8	20
249	A Comparison of How Canadian Primary Care Physicians in Family Health Teams and Solo Physician Practices Manage Cardiometabolic Risk in Patients with Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2012, 36, S39-S40.	0.4	0
250	Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 114-119.	1.0	2
251	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 36-43.	1.0	16
252	Relation Between Previous Angiotensin-Converting Enzyme Inhibitor Use and In-Hospital Outcomes in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2012, 109, 332-336.	0.7	4

#	ARTICLE	IF	CITATIONS
253	Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Tj ETQq1 1 0.784314 rgBT /Over	0.7	18
254	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	13.9	918
255	Has the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early $\beta$ -blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2011, 161, 291-297.	1.2	5
256	Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). <i>Canadian Journal of Cardiology</i> , 2011, 27, 138-145.	0.8	6
257	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. <i>Canadian Journal of Cardiology</i> , 2011, 27, 711-715.	0.8	11
258	Achieving Quality Indicator Benchmarks and Potential Impact on Coronary Heart Disease Mortality. <i>Canadian Journal of Cardiology</i> , 2011, 27, 756-762.	0.8	12
259	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011, 161, 878-885.	1.2	8
260	Risk Stratification in the Setting of Non-ST Elevation Acute Coronary Syndromes 1999-2007. <i>American Journal of Cardiology</i> , 2011, 108, 617-624.	0.7	53
261	The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 211-219.	0.9	3
262	Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2011, 123, 1843-1853.	1.6	147
263	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>European Heart Journal</i> , 2011, 32, 1994-2002.	1.0	34
264	Factors influencing underutilization of evidence-based therapies in women. <i>European Heart Journal</i> , 2011, 32, 1337-1344.	1.0	166
265	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	1.0	41
266	Disparities in Management Patterns and Outcomes of Patients With Non-ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. <i>American Journal of Cardiology</i> , 2010, 105, 1083-1089.	0.7	27
267	Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. <i>American Journal of Cardiology</i> , 2010, 106, 1270-1276.	0.7	34
268	Comparison of Baseline Characteristics, Management and Outcome of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome in Versus Not in Clinical Trials. <i>American Journal of Cardiology</i> , 2010, 106, 1389-1396.	0.7	35
269	Relation Between Hemoglobin Level and Recurrent Myocardial Ischemia in Acute Coronary Syndromes Detected by Continuous Electrocardiographic Monitoring. <i>American Journal of Cardiology</i> , 2010, 106, 1417-1422.	0.7	33
270	Does Enoxaparin Have Enough FINESSE to Replace Unfractionated Heparin in Primary Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 213-214.	1.1	0



#	ARTICLE	IF	CITATIONS
271	Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada. <i>Value in Health</i> , 2010, 13, 915-921.	0.1	55
272	Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1841.	3.8	253
273	Optimal Medical Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 530-537.	0.9	64
274	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. <i>Diabetes Care</i> , 2010, 33, 2558-2560.	4.3	10
275	Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. <i>European Heart Journal</i> , 2010, 31, 2156-2169.	1.0	165
276	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 958-966.	1.0	10
277	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , 2010, 31, 1328-1336.	1.0	51
278	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 667-675.	1.0	63
279	Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010, 139, 123-133.	0.8	44
280	Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY. <i>International Journal of Cardiology</i> , 2010, 144, 36-41.	0.8	23
281	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry. <i>International Journal of Cardiology</i> , 2010, 145, 15-20.	0.8	13
282	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. <i>American Heart Journal</i> , 2010, 159, 40-46.	1.2	24
283	Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. <i>American Heart Journal</i> , 2010, 159, 354-360.	1.2	77
284	QRS prolongation in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2010, 159, 593-598.	1.2	20
285	Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. <i>American Heart Journal</i> , 2010, 159, 605-611.	1.2	11
286	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2010, 160, 420-427.	1.2	22
287	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010, 160, 855-861.	1.2	22
288	Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. <i>Canadian Journal of Cardiology</i> , 2010, 26, 129-134.	0.8	38

#	ARTICLE	IF	CITATIONS
289	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010, 26, 297-302.	0.8	89
290	Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , 2010, 26, e330-e335.	0.8	46
291	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	13.9	560
292	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	13.9	533
293	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2877-2885.	1.6	428
294	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. <i>European Heart Journal</i> , 2009, 30, 549-557.	1.0	84
295	Applying the Evidence. <i>Stroke</i> , 2009, 40, 1417-1424.	1.0	64
296	G-Proteinâ€‘Coupled Receptors as Signaling Targets for Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 449-457.	1.1	102
297	ST Resolution 1 Hour After Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from ASSENT 3. <i>American Journal of Cardiology</i> , 2009, 103, 154-158.	0.7	5
298	Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 103, 1530-1536.	0.7	67
299	Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Nonâ€‘ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY). <i>American Journal of Cardiology</i> , 2009, 104, 1330-1335.	0.7	2
300	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 11-17.	1.0	21
301	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , 2009, 157, 642-650.e1.	1.2	28
302	Pulmonary artery catheterization in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009, 158, 170-176.	1.2	8
303	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009, 158, 193-201.e5.	1.2	165
304	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. <i>American Heart Journal</i> , 2009, 158, 392-399.	1.2	160
305	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in nonâ€‘ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. <i>American Heart Journal</i> , 2009, 158, 917-924.	1.2	18
306	Predictors and Implications of Q-Waves in ST-Elevation Acute Coronary Syndromes. <i>American Journal of Medicine</i> , 2009, 122, 144-151.	0.6	11

#	ARTICLE	IF	CITATIONS
307	Unprotected left main revascularization in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2009, 30, 2308-2317.	1.0	108
308	Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 2705-2718.	13.9	483
309	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. <i>Canadian Journal of Cardiology</i> , 2009, 25, e370-e376.	0.8	32
310	Outcome of patients with acute coronary syndromes enrolled in clinical trials. <i>Coronary Artery Disease</i> , 2009, 20, 473-476.	0.3	1
311	Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores. <i>PLoS ONE</i> , 2009, 4, e7947.	1.1	123
312	Drip-and-ship for acute ST-segment myocardial infarction. The pharmacoinvasive strategy for patients treated with fibrinolytic therapy. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 726-730.	0.3	0
313	Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial. <i>Journal of General Internal Medicine</i> , 2008, 23, 310-316.	1.3	44
314	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. <i>American Journal of Cardiology</i> , 2008, 101, 919-924.	0.7	11
315	Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy. <i>American Journal of Cardiology</i> , 2008, 102, 1142-1145.	0.7	24
316	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008, 29, 609-617.	1.0	233
317	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2008, 30, 321-329.	1.0	108
318	Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008, 129, 233-237.	0.8	3
319	Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2008, 155, 19-25.	1.2	40
320	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 718-724.	1.2	7
321	Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2008, 156, 177-184.	1.2	7
322	Spontaneous reperfusion in ST-elevation myocardial infarction: Comparison of angiographic and electrocardiographic assessments. <i>American Heart Journal</i> , 2008, 156, 248-255.	1.2	56
323	Impact of delayed presentation on management and outcome of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 262-268.	1.2	9
324	Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2008, 156, 769-775.	1.2	17

#	ARTICLE	IF	CITATIONS
325	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 797-803.	1.2	8
326	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. <i>Canadian Journal of Cardiology</i> , 2008, 24, 363-368.	0.8	6
327	Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Canadian Journal of Cardiology</i> , 2008, 24, 705-708.	0.8	8
328	Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. <i>European Heart Journal</i> , 2008, 29, 871-879.	1.0	27
329	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 580-589.	3.3	68
330	Acute ST-Segment Elevation Myocardial Infarction. <i>Chest</i> , 2008, 133, 708S-775S.	0.4	110
331	Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Chest</i> , 2008, 133, 670S-707S.	0.4	145
332	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , 2007, 28, 1072-1078.	1.0	226
333	Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. <i>European Heart Journal</i> , 2007, 28, 1079-1084.	1.0	11
334	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2007, 29, 31-37.	1.0	11
335	Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2007, 116, 2669-2677.	1.6	47
336	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1892.	3.8	744
337	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. <i>Circulation</i> , 2007, 116, 2793-2801.	1.6	213
338	Management Patterns in Relation to Risk Stratification Among Patients With Non-ST Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2007, 167, 1009.	4.3	147
339	Are acute coronary syndromes risk models too complex? reply. <i>European Heart Journal</i> , 2007, 28, 2176-2177.	1.0	0
340	Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , 2007, 153, 493-499.	1.2	15
341	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. <i>American Heart Journal</i> , 2007, 153, 500-506.	1.2	22
342	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2007, 153, 960-969.	1.2	23

#	ARTICLE	IF	CITATIONS
343	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2007, 154, 71-78.	1.2	93
344	Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. <i>American Heart Journal</i> , 2007, 154, 1108-1115.	1.2	141
345	Title is missing!. <i>Canadian Journal of Cardiology</i> , 2007, 23, 398.	0.8	0
346	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: An international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1073-1079.	0.8	41
347	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1124-1130.	0.8	25
348	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 2077-2086.	1.0	172
349	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007, 28, 1717-1722.	1.0	121
350	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 73-83.	0.7	106
351	Comparison of Effectiveness of Enoxaparin Versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2007, 99, 186-188.	0.7	2
352	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. <i>American Journal of Cardiology</i> , 2007, 100, 169-174.	0.7	17
353	Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein $\geq 100$ mg/dl Versus $< 100$ mg/dl. <i>American Journal of Cardiology</i> , 2007, 100, 913-918.	0.7	23
354	Bedtime Administration of Graded-Release Diltiazem in Patients with Inadequate BP Control. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 393-400.	1.0	2
355	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2006, 22, 115-120.	0.8	35
356	Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , 2006, 22, 835-839.	0.8	9
357	Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. <i>Canadian Journal of Cardiology</i> , 2006, 22, 663-677.	0.8	13
358	Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: The TRANSFER-AMI pilot feasibility study. <i>Canadian Journal of Cardiology</i> , 2006, 22, 1121-1126.	0.8	18
359	Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries. <i>Journal of Vascular Surgery</i> , 2006, 44, 776-781.	0.6	18
360	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1346-1354.	1.2	79

#	ARTICLE	IF	CITATIONS
361	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. <i>American Journal of Medicine</i> , 2006, 119, 676-683.	0.6	148
362	Unraveling the spectrum of left bundle branch block in acute myocardial infarction: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. <i>American Heart Journal</i> , 2006, 151, 10-15.	1.2	45
363	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 151, 352-359.	1.2	94
364	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatid. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2006, 151, 373-379.	1.2	32
365	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006, 151, 654-660.	1.2	101
366	The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: The Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. <i>American Heart Journal</i> , 2006, 151, 791-797.	1.2	7
367	The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: Current status in an era of revascularization and reperfusion. <i>American Heart Journal</i> , 2006, 152, 11-18.	1.2	59
368	ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. <i>American Heart Journal</i> , 2006, 152, 270-276.	1.2	26
369	The prognostic value of the admission and predischage electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience. <i>American Heart Journal</i> , 2006, 152, 277-284.	1.2	11
370	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 152, 676-683.	1.2	43
371	Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 211-220.	1.0	12
372	Prognostic Significance of Admission Heart Failure in Patients With Non-ST-Elevation Acute Coronary Syndromes (from the Canadian Acute Coronary Syndrome Registries). <i>American Journal of Cardiology</i> , 2006, 98, 470-473.	0.7	35
373	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ: British Medical Journal</i> , 2006, 333, 1091.	2.4	1,236
374	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. <i>American Journal of Cardiology</i> , 2005, 96, 913-916.	0.7	108
375	Short- and Long-Term Outcomes of Patients With Electrocardiographic Left Ventricular Hypertrophy After Fibrinolysis for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 1050-1052.	0.7	8
376	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 149-157.	0.7	14
377	High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2594.	3.8	57
378	A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. <i>European Heart Journal</i> , 2005, 26, 1726-1733.	1.0	11

#	ARTICLE	IF	CITATIONS
379	Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and nonâ€“ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial. American Heart Journal, 2005, 149, 275-283.	1.2	19
380	Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. American Heart Journal, 2005, 150, 659-665.	1.2	19
381	Predictors and 1-year outcome of major bleeding in patients with nonâ€“ST-elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. American Heart Journal, 2005, 150, 690-694.	1.2	101
382	Management of risk in peripheral artery disease: Recent therapeutic advances. American Heart Journal, 2005, 150, 35-40.	1.2	28
383	Enoxaparin and glycoprotein IIb/IIIa inhibition in nonâ€“ST-elevation acute coronary syndrome: Insights from the INTERACT trial. American Heart Journal, 2005, 149, S73-S80.	1.2	7
384	Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. Canadian Journal of Cardiology, 2005, 21, 85-90.	0.8	3
385	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. Canadian Journal of Cardiology, 2005, 21, 501-7.	0.8	1
386	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. European Heart Journal, 2004, 25, 2006-2012.	1.0	25
387	Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 89-96.	3.8	278
388	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. JAMA - Journal of the American Medical Association, 2004, 292, 45-54.	3.8	702
389	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2004, 291, 2727.	3.8	1,344
390	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). American Journal of Cardiology, 2004, 93, 288-293.	0.7	165
391	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary) Tj ETQq1 1 0.784314 rgBT /Overl 0,7 88	0.7	88
392	Aborted myocardial infarction in patients with ST-segment elevation. Journal of the American College of Cardiology, 2004, 44, 38-43.	1.2	110
393	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2004, 147, 42-48.	1.2	89
394	Clinical trialâ€“derived risk model may not generalize to real-world patients with acute coronary syndrome. American Heart Journal, 2004, 148, 1020-1027.	1.2	84
395	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal, 2004, 148, 269-276.	1.2	10
396	How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. American Heart Journal, 2004, 148, 1028-1033.	1.2	16

#	ARTICLE	IF	CITATIONS
397	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , 2004, 117, 73-81.	0.6	198
398	Acute Coronary Syndromes Without Chest Pain, An Underdiagnosed and Undertreated High-Risk Group. <i>Chest</i> , 2004, 126, 461-469.	0.4	439
399	Low-molecular-weight heparins in ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2004, 19, 309-316.	0.8	6
400	Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. <i>Atherosclerosis</i> , 2003, 171, 255-258.	0.4	18
401	Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. <i>American Heart Journal</i> , 2003, 146, 33-41.	1.2	181
402	Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. <i>American Heart Journal</i> , 2003, 146, 640-645.	1.2	10
403	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2003, 146, 999-1006.	1.2	104
404	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003, 24, 1414-1424.	1.0	225
405	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. <i>Archives of Internal Medicine</i> , 2003, 163, 2345.	4.3	1,856
406	Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide. <i>Circulation</i> , 2003, 107, 238-244.	1.6	200
407	The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. <i>European Heart Journal</i> , 2003, 24, 1024-1034.	1.0	10
408	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. <i>European Heart Journal</i> , 2003, 24, 1515-1522.	1.0	27
409	The development of Partners for Health's integrated community pathway for postmyocardial infarction patients. <i>Canadian Journal of Cardiology</i> , 2003, 19, 231-5.	0.8	1
410	Enoxaparin Treatment in Unstable Coronary Artery Disease. <i>Chest</i> , 2002, 121, 666-667.	0.4	0
411	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). <i>Lancet</i> , The, 2002, 359, 373-377.	6.3	496
412	Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: Results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. <i>American Heart Journal</i> , 2002, 144, 60-67.	1.2	16
413	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , 2002, 89, 791-796.	0.7	271
414	Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. <i>American Heart Journal</i> , 2002, 144, 243-250.	1.2	24



#	ARTICLE	IF	CITATIONS
415	An early invasive strategy reduced the incidence of major cardiac events in patients with unstable coronary syndromes. ACP Journal Club, 2002, 136, 4.	0.1	0
416	Review: oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. ACP Journal Club, 2002, 137, 85.	0.1	0
417	Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes. Canadian Journal of Cardiology, 2002, 18, 1179-90.	0.8	2
418	Abciximab was more effective than tirofiban in preventing ischemic events in patients having coronary stenting. ACP Journal Club, 2002, 136, 5.	0.1	0
419	Review: Oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. ACP Journal Club, 2002, 137, 85.	0.1	0
420	Standards for the function of an academic 12-lead electrocardiographic core laboratory. Journal of Electrocardiology, 2001, 34, 41-47.	0.4	8
421	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb11Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A); Global Use of Strategies To Open occluded arteries in acute coronary syndromes (GUSTO-IIb).. Journal of the American College of Cardiology, 2001, 38, 64-71.	1.2	145
422	Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. Journal of Nuclear Cardiology, 2001, 8, 136-143.	1.4	18
423	Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. American Journal of Cardiology, 2001, 88, 842-847.	0.7	31
424	Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis. Circulation, 2001, 104, 2653-2659.	1.6	101
425	Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction. Circulation, 2001, 103, 954-960.	1.6	32
426	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). American Journal of Cardiology, 2000, 86, 24-29.	0.7	8
427	Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. American Heart Journal, 2000, 139, 423-429.	1.2	55
428	Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. American Heart Journal, 2000, 139, 962-970.	1.2	30
429	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. American Heart Journal, 2000, 140, 385-394.	1.2	23
430	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease—A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447-52.. Journal of the American College of Cardiology, 2000, 36, 693-698.	1.2	154
431	Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. Journal of the American College of Cardiology, 2000, 36, 1507-1513.	1.2	59
432	Exertional sudden coronary death was associated with acute plaque rupture in men. Evidence-based Cardiovascular Medicine, 1999, 3, 61.	0.0	0

#	ARTICLE	IF	CITATIONS
433	Women had a worse prognosis than men after myocardial infarction. ACP Journal Club, 1999, 130, 46.	0.1	0
434	Abciximab and heparin given during coronary interventions reduced combined death, MI, and urgent revascularization. ACP Journal Club, 1999, 131, 40.	0.1	0
435	Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. American Journal of Cardiology, 1998, 82, 19L-24L.	0.7	98
436	Higher T-Wave Amplitude Associated With Better Prognosis in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (a GUSTO-I Substudy) 11This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. American Journal of Cardiology, 1998, 81, 1078-1084.	0.7	25
437	Non-Q-Wave Versus Q-Wave Myocardial Infarction After Thrombolytic Therapy. Circulation, 1998, 97, 444-450.	1.6	72
438	A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. New England Journal of Medicine, 1997, 337, 447-452.	13.9	1,397
439	Thrombolysis and Q Wave Versus Non-Q Wave First Acute Myocardial Infarction: A GUSTO-I Substudy. Journal of the American College of Cardiology, 1997, 29, 770-777.	1.2	47
440	Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction. Journal of the American College of Cardiology, 1996, 27, 1327-1332.	1.2	71
441	Women with acute myocardial infarction had worse prognosis than men. ACP Journal Club, 1996, 125, 43.	0.1	0
442	Coronary angiography in Q-wave versus non-Q-wave acute myocardial infarction. American Journal of Cardiology, 1995, 76, 429-430.	0.7	1
443	Treatment of silent ischemia in unstable angina: A randomized comparison of sustained-release verapamil versus metoprolol. Clinical Cardiology, 1995, 18, 653-658.	0.7	10
444	Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. American Journal of Cardiology, 1994, 74, 657-661.	0.7	22
445	Does ambulatory monitoring contribute to exercise testing and myocardial perfusion scintigraphy in the prediction of the extent of coronary artery disease in stable angina?. American Journal of Cardiology, 1994, 73, 747-752.	0.7	8
446	Acute coronary thrombotic occlusion following exercise testing 6 weeks after percutaneous transluminal coronary angioplasty. Catheterization and Cardiovascular Diagnosis, 1992, 27, 40-44.	0.7	6